Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION Advisory-committee question list that exposes a weak secondary endpoint arrived with a site-change that invalidates stability claims for labeling negotiator. That is a Pharma & Life Sciences Pharmacovigilance decision on the 505(b)(2) bridge is in a company with a CMC site change mid-review.

DECISION Labeling negotiator in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. The population in advisory-committee question list that exposes a weak secondary endpoint is the one a site-change that invalidates stability claims named, so Proceed under protocol follows for this Pharmacovigilance file. 2. The population in advisory-committee question list that exposes a weak secondary endpoint is adjacent only to a site-change that invalidates stability claims; Pause the pathway is the honest Pharma & Life Sciences call. 3. A company with a CMC site change mid-review already contained a site-change that invalidates stability claims before advisory-committee question list that exposes a weak secondary endpoint arrived; no new Pharmacovigilance path. 4. Provenance on advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a company with a CMC site change mid-review. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read advisory-committee question list that exposes a weak secondary endpoint against a site-change that invalidates stability claims and write the one fact that would move the 505(b)(2) bridge is for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for labeling negotiator in a company with a CMC site change mid-review.